The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice

Table 3

Change in DAS28-ESR scores over a 6-month period.

Treatment; as monotherapy or in combination		Month 0; mean (SEM)	Month 6; mean (SEM)	Change over time; value (%)	value
Methotrexate	1,850	3.19 (0.03)	2.89 (0.03)	0.30 (9.4%)	<0.001
Hydroxychloroquine	494	3.33 (0.06)	3.01 (0.06)	0.32 (9.6%)	<0.001
Leflunomide	472	3.53 (0.07)	3.04 (0.06)	0.49 (13.8%)	<0.001
Sulfasalazine	319	3.55 (0.09)	3.09 (0.08)	0.46 (12.9%)	<0.001
Adalimumab	324	2.96 (0.07)	2.86 (0.06)	0.10 (3.4%)	0.106
Etanercept	394	3.15 (0.07)	2.87 (0.06)	0.28 (8.9%)	<0.001
Tocilizumab	128	2.51 (0.112)	2.16 (0.10)	0.35 (13.9%)	0.001